Mark Booth has been appointed chief business officer at Probiodrug AG, which has a treatment for Alzheimer’s disease in clinical development. Mr Booth was previously chief commercial officer at Orexigen Therapeutics and before that, president of Takeda Pharmaceuticals North America. Mr Booth holds a BS in biology from Northern Illinois University and a MBA from the Northwestern University Kellogg School of Management.
Probiodrug announced the appointment on 23 March 2016.
Copyright 2016 Evernow Publishing Ltd